|
|
Article: PharmaNetics Announces Collaborative Sales and Marketing Program with Aventis for Launch of Enoxaparin Test; PharmaNetics Provides Financial Guidance for 2003.
- Article from:
- Business Wire
- Article date:
- January 9, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
RALEIGH, N.C.--(BUSINESS WIRE)--Jan. 9, 2003
PharmaNetics, Inc. (NASDAQ/NM: PHAR), a leader in theranostic management, today announced details for a collaborative marketing program with Aventis Pharmaceuticals Inc., the U.S. pharmaceutical company of Aventis (NYSE:AVE), to coordinate sales, marketing and educational efforts to promote the use of the ENOX test, for which PharmaNetics received FDA clearance in August 2002. The ENOX test is used to detect the anticoagulant effects of Aventis Pharmaceuticals' enoxaparin sodium (Lovenox(R)), the number-one selling low-molecular weight heparin (LMWH) in the world, in ...